Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical · NYSE
$75.06-3.23 (-4.13%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Globus Medical, 10 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $80.00 to $123.00, a moderate spread. The average target of $100.00 sits 33% above the current $75.06. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.34 next quarter toward $5.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1077%
Hold323%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Globus Medical.
As of Sep, 10 of 13 firms rate GMED a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GMED EPS & revenue forecast
EPS · NEXT QUARTER
$1.34
Range $1.31 – $1.39 · 14 analysts · +5% YoY
Next period, 14 analysts expect Globus Medical to earn $1.34 a share (range $1.31 – $1.39), versus $1.28 a year earlier. Full-year consensus is $5.00, growing to $5.40 the year after.
REVENUE · NEXT QUARTER
$857.9M
Range $842.7M – $877.0M · 14 analysts · +4% YoY
Revenue is expected to reach $857.9M (range $842.7M – $877.0M), +3.8% year-over-year. Full-year consensus is $3.2B, rising to $3.4B next year.
Top analysts covering Globus Medical
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GMED.
#1
CC
Caitlin Cronin
Canaccord Genuity · Rank #192
Buy
$115.00+53.2% to target
Overall win rate
40%
+ Follow
#2
William Plovanic
Canaccord Genuity · Rank #243
Buy
$90.00+19.9% to target
Overall win rate
37%
+ Follow
#3
JW
Jason Wittes
Roth MKM · Rank #311
Buy
$105.00+39.9% to target
Overall win rate
39%
+ Follow
#4
David Turkaly
JMP Securities · Rank #346
Hold
No targeton GMED
Overall win rate
33%
+ Follow
#5
David Saxon
Needham · Rank #347
Buy
$117.00+55.9% to target
Overall win rate
32%
+ Follow
GMED stock forecast FAQ
What is GMED's average 12-month price target?+
The 12 analysts with a live target average $100.00 for Globus Medical over the next 12 months, ranging from a $123.00 high to a $80.00 low.
Is GMED stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 10 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GMED?+
The Street-high target is $123.00 (Barclays), and the Street-low is $80.00 (Stifel). The average of all 12 active targets is $100.00.
How many Wall Street analysts cover GMED?+
13 analysts have an active rating on Globus Medical, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering GMED?+
Among analysts who currently cover GMED, Caitlin Cronin of Canaccord Genuity has the strongest overall Quantellect track record (Rank #192). Their current call is Buy with a $115.00 target.
What is Globus Medical's projected EPS for next quarter?+
The consensus estimate is $1.34 per share (range $1.31 – $1.39) across 14 analysts. Full-year EPS is projected at $5.00, rising to $5.40 the following year.
How much revenue is Globus Medical expected to report next quarter?+
Consensus revenue is $857.9M (range $842.7M – $877.0M). Full-year revenue is projected at $3.2B, growing to $3.4B next year.
Have analysts been upgrading or downgrading GMED lately?+
As of Sep, 10 of 13 firms rate GMED a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GMED calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
